Ascendis Presents Updated and New TransCon IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023

26.10.2023 - —  Clinical responses with TransCon IL-2 β⁄γ demonstrated as monotherapy or in combination with checkpoint inhibitor, including in two of three small cell lung cancer patients treated with combination therapy — TransCon IL-2 β⁄γ administered every ... Seite 1

Related Keywords

Copenhagen ,Køavn ,Denmark ,Spain ,Madrid ,Stina Singel ,Ascendis Pharma ,Head Of Clinical Development ,European Society Of Medical Oncology ,Believe Trial ,European Society ,Medical Oncology ,Executive Vice President ,Clinical Development ,Ascendis Pharma Chart ,Scendis Pharma Kurs ,Scendis Pharma Aktie ,